Drug Comparison
Retatrutide vs Semaglutide: 28.7% vs 14.9% Weight Loss
Semaglutide (Wegovy, Ozempic) set the modern standard for anti-obesity pharmacotherapy in 2021. Retatrutide, if approved, would nearly double that weight loss ceiling. Here's what the data shows — and what it means for patients today.
⚠ Investigational drug — not FDA-approved
Retatrutide is currently in Phase 3 clinical trials. It is not available by prescription and not approved for human use outside of clinical trials. This page is educational only.
Retatrutide (Phase 3)
28.7%
TRIUMPH-3 · 48 weeks
Triple agonist (GIP/GLP-1/glucagon)
⚠ Not FDA-approved
Semaglutide 2.4 mg (Approved)
14.9%
STEP-1 · 68 weeks
GLP-1 receptor agonist
✓ FDA-approved (Wegovy)
Side-by-Side Comparison
| Feature | Retatrutide | Semaglutide 2.4 mg |
|---|---|---|
| Brand Name | None (investigational) | Wegovy (obesity); Ozempic (T2D) |
| Developer | Eli Lilly | Novo Nordisk |
| Mechanism | GIP + GLP-1 + Glucagon receptor agonist | GLP-1 receptor agonist only |
| FDA Status | Phase 3 Investigational | Approved 2021 (Wegovy) |
| Phase 3 Weight Loss | 28.7% (TRIUMPH-4) | 14.9% (STEP-1) |
| Max Dose | 12 mg/week | 2.4 mg/week |
| Frequency | Once weekly | Once weekly |
| Cash Price/Month | Not priced (not approved) | ~$1,349/month (Wegovy) |
| Availability | Clinical trials only | Prescription, broad availability |
| SELECT CV trial | Not yet — TRIUMPH CV trial ongoing | Yes — 20% MACE reduction (2024) |
The 13.8 Percentage Point Gap
The difference between 14.9% (semaglutide, STEP-1) and 28.7% (retatrutide, TRIUMPH-4) is substantial in clinical terms. For a 250 lb person:
- Semaglutide 2.4 mg: ~37 lbs expected loss at 14.9%
- Retatrutide 12 mg: ~72 lbs expected loss at 28.7%
The additional ~35 lbs of expected weight loss could represent the difference between partial metabolic normalization and achieving a healthy BMI for many patients. Remission of type 2 diabetes, improvement in obstructive sleep apnea, and cardiovascular risk reduction are all dose-dependent and improve further with greater weight loss.
Why Does Triple Agonism Outperform Single GLP-1?
Semaglutide is a highly optimized GLP-1 receptor agonist. It efficiently suppresses appetite and slows gastric emptying. But it doesn't:
- Activate GIP receptors (which enhance GLP-1 effects and may reduce nausea)
- Activate glucagon receptors (which increase energy expenditure and promote fat oxidation)
Retatrutide's triple mechanism attacks obesity from three angles simultaneously — input (appetite), throughput (gastric emptying and satiety), and output (energy expenditure and fat burning). The glucagon component in particular appears to be a meaningful driver of the incremental efficacy seen in Phase 2 and Phase 3 data.
Where Semaglutide Still Has Advantages Today
Despite lower weight loss efficacy compared to retatrutide, semaglutide has important established advantages:
- Cardiovascular data: The SELECT trial (2023/2024) demonstrated a 20% reduction in MACE in adults with obesity and established CVD — retatrutide has no comparable cardiovascular outcomes trial yet
- Long-term safety profile: Approved since 2021, millions of patients have used semaglutide; long-term data beyond 5 years is accumulating
- Availability now: Retatrutide is not available; semaglutide can be prescribed today
- Oral formulation (Rybelsus): Semaglutide has an approved once-daily oral tablet — no injectable equivalent for retatrutide is in development
- Cost: Semaglutide has manufacturer savings programs, established formulary coverage, and compounded alternatives
Decision Framework
If you need treatment today: semaglutide (Wegovy) is an excellent, proven option. Use our Weight Loss Projector to estimate your expected outcomes on semaglutide vs tirzepatide (a higher-efficacy approved alternative).
If retatrutide's efficacy profile is compelling and your clinical situation allows: monitor the TRIUMPH trial program via our trial tracker, discuss clinical trial eligibility with your physician, or plan to discuss retatrutide with your prescriber upon potential approval in 2027–2028.
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)." NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- TRIUMPH-3 data — Eli Lilly Phase 3 press release. [verify: primary source upon publication]
Frequently Asked Questions
When will retatrutide be available compared to semaglutide?
Semaglutide (Wegovy, Ozempic) has been FDA-approved and broadly prescribed since 2021. Retatrutide is in Phase 3 trials (TRIUMPH program) with pivotal results expected 2026–2027 and possible commercial launch 2027–2028 if approved.
Is retatrutide just 'better' semaglutide?
It is mechanistically different, not just stronger. Semaglutide activates only the GLP-1 receptor. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component appears to drive much of the additional weight loss by increasing energy expenditure.
Will retatrutide have the same cardiovascular benefits as semaglutide?
Unknown. Semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events for adults with obesity and established cardiovascular disease. Retatrutide has no comparable cardiovascular outcomes trial completed. The TRIUMPH-CV trial is ongoing.
Can I take retatrutide and semaglutide together?
No. Both medications act on overlapping receptor systems. Combining them would increase risk of severe gastrointestinal side effects without established benefit. Switching, not combining, is the appropriate clinical pathway and only under prescriber supervision.
If retatrutide produces nearly 2x the weight loss, why would anyone stay on semaglutide?
Availability is the biggest reason — retatrutide cannot be prescribed today. Beyond that, semaglutide has documented cardiovascular benefit, a 5+ year post-marketing safety database, and an oral formulation (Rybelsus). For patients tolerating semaglutide well with good results, switching to an unstudied alternative would be premature.